News Channels

27 Jul 2017 Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery
27 Jul 2017 NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
27 Jul 2017 Arbutus Announces Conclusion of LNP License Agreement with Alexion
27 Jul 2017 Moderna Provides Update on mRNA Rare Disease R&D Strategy
27 Jul 2017 Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
27 Jul 2017 Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®
27 Jul 2017 Samumed Successfully Completed 52-Week Phase 2 Study for Treatment of Osteoarthritis of the Knee
27 Jul 2017 Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events
27 Jul 2017 Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
27 Jul 2017 Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
27 Jul 2017 Chikungunya-fever: Themis Bioscience starts phase II clinical study in endemic area
27 Jul 2017 Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets
27 Jul 2017 Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
27 Jul 2017 Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies
27 Jul 2017 Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B
27 Jul 2017 Evotec Expands Collaboration with Storm Therapeutics on Its RNA Epigenetics Platform
27 Jul 2017 Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology
27 Jul 2017 CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine
27 Jul 2017 FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures
27 Jul 2017 Tesaro and Takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in Japan

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top